403 related articles for article (PubMed ID: 27888902)
1. [Unmet needs: patients with statin intolerance or familial hypercholesterolemia].
Masana L; Civeira F
Clin Investig Arterioscler; 2016 May; 28 Suppl 2():22-30. PubMed ID: 27888902
[TBL] [Abstract][Full Text] [Related]
2. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
[TBL] [Abstract][Full Text] [Related]
3. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
Agabiti Rosei E; Salvetti M
High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
[TBL] [Abstract][Full Text] [Related]
4. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
5. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.
Teramoto T; Kondo A; Kiyosue A; Harada-Shiba M; Ishigaki Y; Tobita K; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
Lipids Health Dis; 2017 Jun; 16(1):121. PubMed ID: 28623954
[TBL] [Abstract][Full Text] [Related]
8. [Lipid control in high-risk patients: focus on PCSK9 inhibitors].
Filardi PP; Paolillo S; Trimarco B
G Ital Cardiol (Rome); 2015 Jan; 16(1):44-51. PubMed ID: 25689751
[TBL] [Abstract][Full Text] [Related]
9. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
[TBL] [Abstract][Full Text] [Related]
10. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
[TBL] [Abstract][Full Text] [Related]
11. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy.
Hartgers ML; Besseling J; Stroes ES; Wittekoek J; Rutten JHW; de Graaf J; Visseren FLJ; Imholz BPM; Roeters van Lennep JE; Huijgen R; Kastelein JJP; Hovingh GK
J Clin Lipidol; 2018; 12(4):972-980.e1. PubMed ID: 29934068
[TBL] [Abstract][Full Text] [Related]
12. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F;
Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826
[TBL] [Abstract][Full Text] [Related]
13. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P
Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977
[TBL] [Abstract][Full Text] [Related]
14. [Up to date lipid lowering treatment].
Paragh G; Karádi I
Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
[TBL] [Abstract][Full Text] [Related]
15. [PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated?Czech atherosclerosis society statement].
Soška V; Vrablík M; Bláha V; Cífková R; Češka R; Freiberger T; Kraml P; Piťha J; Rosolová H; Štulc T; Vaverková H; Urbanová Z
Vnitr Lek; 2016 Apr; 62(4):329-33. PubMed ID: 27250613
[TBL] [Abstract][Full Text] [Related]
16. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials.
Ridker PM; Amarenco P; Brunell R; Glynn RJ; Jukema JW; Kastelein JJ; Koenig W; Nissen S; Revkin J; Santos RD; Schwartz PF; Yunis C; Tardif JC;
Am Heart J; 2016 Aug; 178():135-44. PubMed ID: 27502861
[TBL] [Abstract][Full Text] [Related]
17. Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study.
Cho L; Rocco M; Colquhoun D; Sullivan D; Rosenson RS; Dent R; Xue A; Scott R; Wasserman SM; Stroes E
Cardiovasc Drugs Ther; 2016 Jun; 30(3):297-304. PubMed ID: 26936841
[TBL] [Abstract][Full Text] [Related]
18. PCSK9 inhibitors--past, present and future.
Reiner Ž
Expert Opin Drug Metab Toxicol; 2015; 11(10):1517-21. PubMed ID: 26329686
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
Okere AN; Serra C
Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
[TBL] [Abstract][Full Text] [Related]
20. Alirocumab for the treatment of hypercholesterolaemia.
Della Pepa G; Bozzetto L; Annuzzi G; Rivellese AA
Expert Rev Clin Pharmacol; 2017 Jun; 10(6):571-582. PubMed ID: 28395555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]